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Abstract
Background: Expanded access to antiretroviral therapy (ART) using universal test and treat (UTT) has been suggested as a
strategy to eliminate HIV in South Africa within 7 y based on an influential mathematical modeling study. However, the
underlying deterministic model was criticized widely, and other modeling studies did not always confirm the study’s
finding. The objective of our study is to better understand the implications of different model structures and assumptions,
so as to arrive at the best possible predictions of the long-term impact of UTT and the possibility of elimination of HIV.
Methods and Findings:We developed nine structurally different mathematical models of the South African HIV epidemic in
a stepwise approach of increasing complexity and realism. The simplest model resembles the initial deterministic model,
while the most comprehensive model is the stochastic microsimulation model STDSIM, which includes sexual networks and
HIV stages with different degrees of infectiousness. We defined UTT as annual screening and immediate ART for all HIV-
infected adults, starting at 13% in January 2012 and scaled up to 90% coverage by January 2019. All models predict
elimination, yet those that capture more processes underlying the HIV transmission dynamics predict elimination at a later
point in time, after 20 to 25 y. Importantly, the most comprehensive model predicts that the current strategy of ART at CD4
count #350 cells/ml will also lead to elimination, albeit 10 y later compared to UTT. Still, UTT remains cost-effective, as many
additional life-years would be saved. The study’s major limitations are that elimination was defined as incidence below 1/
1,000 person-years rather than 0% prevalence, and drug resistance was not modeled.
Conclusions: Our results confirm previous predictions that the HIV epidemic in South Africa can be eliminated through
universal testing and immediate treatment at 90% coverage. However, more realistic models show that elimination is likely
to occur at a much later point in time than the initial model suggested. Also, UTT is a cost-effective intervention, but less
cost-effective than previously predicted because the current South African ART treatment policy alone could already drive
HIV into elimination.
Please see later in the article for the Editors’ Summary.
Citation: Hontelez JAC, Lurie MN, Ba¨rnighausen T, Bakker R, Baltussen R, et al. (2013) Elimination of HIV in South Africa through Expanded Access to Antiretroviral
Therapy: A Model Comparison Study. PLoS Med 10(10): e1001534. doi:10.1371/journal.pmed.1001534
Academic Editor: Nathan Ford, World Health Organization, Switzerland
Received October 12, 2012; Accepted September 5, 2013; Published October 22, 2013
Copyright:  2013 Hontelez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work is supported by the HIV Modelling Consortium. The HIV Modelling Consortium is supported by a grant from the Bill & Melinda Gates
Foundation to Imperial College London. This work is also supported by the US National Institutes of Health (1R01MH083539–01) and (1R01-HD058482–01). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: TBH and MLN are members of the PLOS Medicine Editorial Board. TBH is the director of the HIV Modelling Consortium, a project funded
by the Bill & Melinda Gates Foundation, which contributed funding toward this study. TBH did not have a role in deciding that funding should be awarded to this
team. All other authors have declared that no competing interests exist.
Abbreviations: ART, antiretroviral therapy; FSW, female sex worker; STI, sexually transmitted infection; UNAIDS, Joint United Nations Programme on HIV/AIDS;
UTT, universal test and treat; WHO, World Health Organization.
* E-mail: j.hontelez@erasmusmc.nl
PLOS Medicine | www.plosmedicine.org 1 October 2013 | Volume 10 | Issue 10 | e1001534
Introduction
South Africa is home to the largest population of HIV-infected
individuals worldwide, with nearly 6 million people living with
HIV in 2010 [1]. Although extensive efforts to curb the epidemic
may have resulted in some decline in the number of new HIV
infections among young adults in the past few years [2,3],
incidence levels remain considerable. The proof of concept that
antiretroviral therapy (ART) can be used to prevent onward trans-
mission [4,5], created renewed excitement that a turning point in
the ever-growing HIV epidemic could be achieved by expanding
access to treatment. ‘‘Treatment as prevention’’ (treatment of all
HIV-infected individuals with ART, regardless of CD4 cell count,
in order to reduce transmission)—a hypothesized HIV prevention
intervention that is currently being tested in community randomized
trials [6]—was conceptually designed by mathematical models [7–
13]. In 2009, Granich et al. suggested that the HIV epidemic in
South Africa could be driven into an elimination phase (defined as
an incidence of below one new infection per 1,000 person-years)
after just 7 y of annual HIV screening for individuals aged 15 y and
older and immediate ART for all HIV-infected patients (universal
test and treat [UTT]) [9].
In response to these results, other modeling studies also examined
the potential impact of a UTT intervention in various settings [14–
19]. But there are as many different conclusions as there are models
that investigated the issue. As models are profoundly different in
many aspects—structure, parameterization, and assumptions about
the intervention—it is difficult to determine which factors are respon-
sible for the differences in the model predictions [20]. There are
several obvious reasons for these discrepancies, such as differences in
the time horizon of the analysis [14], less or more optimistic assump-
tions regarding programmatic efficacy [14,18], or different assump-
tions about HIV natural history, heterogeneity in transmission, and
ART effectiveness in reducing infectiousness [17]. For example,
Granich et al. assumed a 99.4% reduction in infectiousness of those
on ART [9], but later studies suggested that this reduction is likely to
be too optimistic [4,21–23]. The HPTN 052 trial showed a reduction
of 96% [4] with trial participants completely adhering to treatment,
which is unlikely in large-scale interventions. A Cochrane review
including all observational studies and the HPTN 052 trial reported a
Figure 1. Stepwise approach of developing nine structurally different models with increasing complexity and realism. Model A
resembles the deterministic model used by Granich et al. [9], now simulated using an event-driven approach. Models A and B are fitted to predict
UNAIDS prevalence levels for South Africa by tuning the HIV transmission probabilities and year of HIV introduction. In addition, similar to Granich et
al. [9], models A and B use a prevalence density function to explain the steady-state HIV prevalence observed in South Africa. Models C and D are
fitted to represent UNAIDS-predicted HIV prevalence by adjusting overall partner change rates and the year of HIV introduction. A prevalence density
function is no longer used, and the scaling-up of condom use in the late 1990s/early 2000s—introduced in model C2 and consistent with
observations [2,3]—is now used to explain the steady-state HIV prevalence in South Africa. Finally, models C and D allow for more realistic
assumptions on the effectiveness of ART in reducing infectiousness (infectiousness reduction of 90% [20–22] instead of 99.4%; survival twice as high
[26]).
doi:10.1371/journal.pmed.1001534.g001
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reduction in transmission of about 86% [21]. Also, the ongoing
treatment rollout following the 2010 World Health Organization
(WHO) treatment guidelines of ART at CD4 cell counts of #350
cells/ml [24] will already have a profound impact on the HIV
epidemic [25,26], making it important to compare the impact of
UTT with the current treatment scale-up. Nevertheless, these
obvious differences explain only part of the variation between model
predictions [20]. As modeling remains essential to further inform
public health decision-making, it is vital to better understand the
reasons for the discrepancies between models.
We examined the impact of model structure and parameteri-
zation on the estimated impact of UTT in South Africa in a highly
controlled experiment as follows: we developed nine structurally
different models of the South African HIV epidemic with a
standardized core set of assumptions but with gradated degrees of
model complexity and realism that span from the very simplest to
one of the most comprehensive representations of HIV epidemics
(Figure 1). In all models, we examined the impact of the UTT
intervention suggested by Granich et al. [9] and related this to a
baseline of no UTT (i.e., no ART in the simplest models, and
rollout of ART at CD4 count#350 cells/ml as currently applied in
South Africa in the most detailed model).
Methods
We developed four structurally different main models (models
A, B, C, and D) and five sub-models (sub-models B1, B2, C1, C2,
and C3) of the South African HIV epidemic through a stepwise
approach of increasing complexity and realism (Figure 1; Table 1).
With all models, we compare the impact of UTT to a no-UTT
counterfactual (i.e., no ART in models A to C, and rollout of ART
at CD4 count #350 cells/ml as currently applied in South Africa
in model D). We used the STDSIM framework as a basis for all
nine models. STDSIM is a stochastic microsimulation model that
simulates the life course of individuals in a dynamic network of
sexual contacts [27]. Events like partnership formation and the
acquisition of infection are the result of random processes,
determined by probability distributions. Therefore, the results
are subject to stochastic variation, and the results in our study are
based on the average of 1,000 runs.
The STDSIM model consists of four modules: demo-
graphy, sexual behavior, transmission and natural history, and
interventions. The demography module covers the processes of
birth, death, and migration. Processes for initiation and dissolution
of sexual relationships, mixing according to age preference, sexual
contacts within relationships, and sexual contacts between female
sex workers (FSWs) and their male clients are defined in the sexual
behavior module. In the transmission and natural history module,
transmission probabilities per sexual contact are specified for HIV
and five other sexually transmitted infections (STIs): chancroid,
chlamydia, gonorrhea, syphilis, and herpes simplex virus 2. The
interventions module specifies the timing and effectiveness of
control measures in curbing transmission (e.g., condom use) or
enhancing survival (e.g., ART). STDSIM has been extensively
used to evaluate behavioral interventions [28–31], syndromic
treatment for STIs [32,33], male circumcision [34], different HIV
epidemics in sub-Saharan Africa [35], and, more recently, the
impact of ART on HIV epidemics [25,36–38]. STDSIM can be
used in various levels of complexity by adding or removing com-
ponents from the model. We exploit this flexibility to evaluate the
test and treat strategy with alternative model structures.
Model A
Model A fully resembles the deterministic model developed by
Granich et al. [9], but now simulated using an event-driven
stochastic approach. All individuals in the model constitute a
homogeneous mixture of people in which HIV spreads from
person to person. Individuals are assumed to have a one-off
sexual contact with a random individual of the opposite sex every
8.5 d. We simulate a population aged 15–65 y with a constant
background mortality rate of 0.025 per year. HIV is modeled in
four consecutive stages with equal duration (30 mo) and
transmission probabilities, and is introduced in the model by
randomly ‘‘infecting’’ ten men and ten women. ART is assumed
to decrease infectiousness by 99%, and the duration of the HIV
stages for patients on ART is twice the duration of the stages for
ART-naı¨ve individuals [9]. In addition, as in the Granich model,
transmission rates are further reduced by 40% because of
simultaneous scale-up of other prevention interventions [9]. In
accordance with Granich et al., we adjust transmission rates
according to HIV prevalence through a prevalence density
function to arrive at the observed steady state in HIV prevalence
[9]: p(t1) = p(t0)6e
2xP; where p = HIV transmission probability and
P = HIV prevalence.
Table 1. Overview of successive addition of components and structures to each of the nine models.
Component Model A
Sub-Model
B1
Sub-Model
B2 Model B
Sub-Model
C1
Sub-Model
C2
Sub-Model
C3 Model C Model D
Prevalence density functiona X X X X X
Age-structured population X X X X X X X
Transmission probability by
disease stage
X X X X X X X
Heterogeneity in sexual
behavior
X X X
STI co-factors, male
circumcision, and condom use
X X X
Up-to-date ART effectiveness
assumptions
X X X
Current ART scale-up from 2003
onwards
X
aThis artificial prevalence density function was introduced by Granich et al. [9] to mimic processes that result in the observed leveling off of the HIV epidemic. In the
more comprehensive models of our analysis we replaced this prevalence density function by the actual processes that may be responsible for the leveling off.
doi:10.1371/journal.pmed.1001534.t001
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Model B
To arrive at model B, we extended model A by adding the age-
specific fertility and background mortality rates of South Africa
(sub-model B1), and different stages of HIV disease progression
(acute infection, asymptomatic infection, symptomatic infection,
and AIDS—sub-model B2). Births are assigned randomly to sexually
active women between the ages 15 and 49 y, and the probability of
having a child depends on the age of the woman. We parameterized
the model with Unite Nations–reported data on age-specific fertility
rates for South Africa (Table S1) [39]. The resulting initial total
fertility rate (defined as the expected lifetime number of births per
woman) equals 4.9 births per woman. We reduced all age-specific
fertility rates with equal factors in order to capture declines in fertility
rates as observed in South Africa (Figure S1A) [39]. At birth, the age
at (non-HIV) death of each individual is drawn from predefined sex-
specific survival curves. In order to obtain background mortality
rates in the absence of HIV for South Africa, we corrected the age-
and sex-specific mortality rates for South Africa reported by WHO
[40] using the cause-specific mortality estimates from WHO burden
of disease estimates [41]. The resulting survival curve is shown in
Figure S1B.
In sub-model B2, we added the following HIV disease progres-
sion: (i) early/acute infection with a median duration of 3 mo, (ii)
asymptomatic infection with a median duration of 5 y, (iii) symp-
tomatic infection with a median duration of 4 y, and (iv) AIDS
with a median duration of 8 mo. All stages are exponentially
distributed, and the resulting overall survival distribution has a
median of 10 y and an interquartile range of 8 to 13 y, consistent
with observations [42,43]. Relative to asymptomatic infection (second
stage), transmission probabilities are increased by a factor 15 during
early/acute infection, a factor three during symptomatic infection, and
a factor 7.5 during the AIDS stage [35,44]. In addition, we assumed
that the sexual activity of HIV-infected patients in the AIDS stage
(last 40 wk of life) is reduced by 50% because of ill health [45].
Model C
We extended model B with three components to arrive at model
C. We added heterogeneity in sexual behavior (sub-model C1) by
including different kinds of relationships. We use the same patterns
of mixing as recently used by Hontelez et al. for a rural South
African setting (the Hlabisa sub-district of KwaZulu-Natal)
[25,36,37]. The model contains three types of sexual relationships:
steady relationships, casual relationships, and commercial sex. The
formation of partnerships occurs according to a supply-and-
demand-based mechanism. People become available for a sexual
relationship at an ‘‘age of sexual debut’’ that is randomly drawn at
birth from a uniform distribution (Table S2). Each time the
partnership status of a person changes (e.g., a partnership is
formed or ended), a new duration until the person becomes
available for a new relationship (‘‘time until availability’’) is drawn
from a predefined exponential distribution with m being the mean
time until availability defined as: m= ts,r/(rs,a6p), with ts,r = time
interval by person’s sex (s) and relationship status (r), rs,a = specific
promiscuity factor by sex (s) and age (a), and p = personal promi-
scuity factor. The personal promiscuity factor (p) reflects the
heterogeneity between individuals in the tendency to form
partnerships, and is given by a gamma distribution with an
average value (pm) of 1.0, and a shape parameter of 1.5 [35].
The duration of the availability period of an individual is given
by an exponential distribution, with mean time to find (k) defined
as: d
rs,a|p
, where the value of d is 0.25 y for men and 2.25 y for
women (Table S2) [30]. rs,a and p are explained above. When a
person is available for a new relationship, he/she can be selected
by an individual of the opposite sex who is at the end of his/her
availability period. If a person has not been selected by the end of
his/her availability period, he/she will select a partner from the
pool of available persons of the opposite sex. The type of
relationship (steady or casual) that is formed when a partner is
selected depends on the age of the male partner, and is defined as
the probability of a steady relationship (Table S2). The probability
of a new relationship being a casual relationship is given by one
minus the probability of a steady relationship. A relationship starts
with a sexual contact. After each contact, the time until a new
sexual contact q within the relationship is drawn from an
exponential distribution with a mean frequency of sexual contact
depending on relationship type and the age of the male partner
(Table S2). Finally, the duration of a new relationship is drawn
from an exponential distribution, where the average relationship
duration depends on the relationship type (Table S2).
Partner selection at the end of the time to find k is guided
through an age preference matrix (Table S3), which defines the
probability of selecting a partner from a certain age class. When
there is no partner available in the preferred age class, immediate
resampling is done of a new preferred age class using the remain-
ing age groups with a probability larger than 0. If no partner can
be found in any of the age classes, a new k value is drawn from the
above described equation. Probabilities in the age preference
matrix are chosen to have men prefer slightly younger women.
Preference matrices for both sexes are given in Table S3.
In the model, men can have sexual contacts with FSWs. A
man’s frequency of sexual contacts with a FSW is determined by
defining frequency classes (in this study 0, 1, and 12 times per year
[25,35]). For each class, the proportion of men with and without a
steady relationship falling in that category can be specified. A
personal ‘‘prostitute-visiting inclination,’’ assigned to each male at
birth, determines which individual men are assigned to which
frequency classes. At sexual debut and at each sexual contact with
a FSW, the next sexual contact with a FSW is scheduled according
to an exponential distribution, with the mean duration until next
contact based on the FSW contact frequency class of the individual.
The number of FSWs in the model results from male demand.
New FSWs are recruited from sexually active women with a
defined age range. The number of available FSWs and their
predefined number of clients per week is checked each year and
matched with the number of male contacts with FSWs. If the
number FSWs is too low, new FSWs are recruited. If the number
is too high, a random selection of FSWs terminate their career. For
this study, we used the same values for number of FSWs and
number of male contacts with FSWs as previously used for
KwaZulu-Natal, South Africa [25] (Table S4).
In model C2, we added male circumcision (prevalence = 35%
[46,47]; reduces the risk of HIV acquisition by 50% [48–50]) and
STIs that act as co-factors for HIV transmission (chlamydia,
gonorrhea, chancroid, syphilis, and herpes simplex virus 2).
Natural history and transmission assumptions for all STIs are
described in Table S5. In addition, the model allows for increasing
rates of condom use in the late 1990s/early 2000s, consistent with
observations [2,3], to replace the prevalence density function used
in models A and B.
Sub-model C3 uses more up-to-date assumptions regarding the
effectiveness of ART in reducing HIV transmission and enhancing
survival. Granich et al. assumed that ART reduces infectiousness
by 99% [9]. However, recent observational studies and a
randomized controlled trial showed that effectiveness is likely to
be lower [21–23]. A meta-analysis of observational studies found
an average reduction of 92% [22], which was later also reported
by Donnell et al. [23]. The HPTN 052 trial showed a reduction of
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96% [4]; however, the participants in the trial were completely
adherent to treatment, which is unlikely in large-scale interven-
tions. A Cochrane review including all observational studies and
the HPTN 052 trial reported a reduction in transmission as a
result of ART of about 86% [21]. Here, we assume a 90% efficacy
in reducing transmission, implicitly allowing for imperfect
adherence. In addition, Granich et al. assumed that ART increases
survival of HIV-infected patients by a factor of two relative to their
remaining life expectancy without HIV treatment. We assume the
survival benefit of ART to be twice as high as assumed by Granich
et al. (i.e., a factor four increase), consistent with observations [51].
Model D
Model D resembles the full STDSIM model [25,35–38],
consisting of all of the features in model C but with two important
additions: CD4 cell count decline during disease progression and
the ART rollout in South Africa for the period 2004–2011. Based
on data from Orange Farm, South Africa, we assumed that the
initial (HIV-negative) CD4 cell count in the population follows a
lognormal distribution with median 7.02 (equivalent to 1,116
cells/ml) [52]. CD4 cell counts decline by 25% during acute
infection, and decline linearly over the other stages until the CD4
cell count reaches 0.5% of its initial value, after which an
individual dies of AIDS [9,25,52]. Therefore, based on average
HIV-negative CD4 cell counts and duration of HIV infection, an
individual will, on average, reach a CD4 cell count of #350 cells/
ml about 6 y following infection, and at that point will have a
remaining life expectancy of about 4 y.
In the model, ART coverage is the result of two components: (i)
an individual’s demand for ART as a function of HIV disease
stage, and (ii) the capacity of the health system to meet this
demand. ART coverage in our model is the ART demand met by
the capacity of the health system. We assumed the ART demand
function to be the same as previously estimated for the Hlabisa
sub-district of KwaZulu-Natal, South Africa [25], in which about
30% of all infected individuals first seek care for HIV well after
their CD4 cell count has dropped below 200 cells/ml. We fitted the
model predictions to observed ART coverage levels over the
period July 2004–July 2010 by performing a grid search on three
parameters: start year of ART scale-up, rate of ART scale-up, and
ART scale-up function (three options: linear, square-root, or
quadratic). We optimized predicted ART coverage by calculating
the mean squared error of predicted ART coverage in the model
compared to coverage data reported by WHO [53]. We assumed
that eligibility criteria changed from ART at CD4 count #200
cells/ml to ART at CD4 count #350 cells/ml in August 2011, and
that ART scale-up continued according to the estimated scale-up
pattern for the years 2012–2050 in the baseline.
Model Fitting and Parameter Uncertainty
We fitted all models to replicate the observed HIV prevalence in
South Africa as reported by the Joint United Nations Programme
on HIV/AIDS (UNAIDS) [1]. For each model, we used the
parameters of three aspects that link directly to three different
characteristics of the HIV epidemic in South Africa: (i) the start of
the epidemic, (ii) the growth of the epidemic over the 1990s, and
(iii) leveling off of the epidemic in the early 2000s. We obtained the
best fit by minimizing the squared errors of predicted and reported
HIV prevalence over the period 1990–2010.
We used the following parameters to fit the models/sub-models
A, B1, B2, B, and C3: (i) year of HIV introduction, (ii) transmission
probabilities in men with asymptomatic HIV; (iii) the x parameter
in the prevalence density function. We fitted sub-model C1 in 2
parts: (i) the initial growth of the epidemic in the 1990s, and (ii) the
leveling off of the epidemic in the 2000s. For step 1, we fitted three
parameters: year of HIV introduction, HIV transmission proba-
bilities in individuals with asymptomatic HIV, and relative partner
change rates (multiplying all values of sex- and age-specific
promiscuity—see above—by a certain factor). For step 2, we
assumed changes in the observed leveling off of the HIV epidemic
to be the result of behavior change—defined as changes in relative
partner change rates—and used three parameters: year of start of
behavior change, rate of change in behavior change, and end year
of behavior. The sexual behavior pattern resulting from the best fit
by sex and age for the year 1990 (start of the epidemic) is given in
Figure S2, and for the year 2003 (after above described reduction
in risk behavior) in Figure S3. We used the following parameters to
fit sub-model C2 to observed HIV prevalence levels: (i) year of
introduction of HIV, (ii) transmission probabilities in individuals
with asymptomatic HIV, and (iii) scale-up of condom use over
time. We assume a stepwise linear increase of condom use over
time, and estimate the start year, slope, and end year of the scale-
up that results in the best-fitting HIV prevalence. For models C
and D, we fixed the HIV transmission probability in individuals
with asymptomatic HIV at 0.001 for men and 0.0005 for women
[12]. In order to start the epidemic, we introduced HIV in six
FSWs. We used the following parameters to fit the model: (i) year
of HIV introduction, (ii) relative partner change rates, and (iii) start
year, rate, and end year of condom use scale-up in casual relations
and commercial sex. The best fit for model D resulted in a 30%
condom use rate in casual relationships, which is comparable to
data [54].
We calculated a range around the baseline estimates reflecting
the uncertainty in the parameters that were used to fit all nine
models. We developed uniform distributions with intervals wide
enough to capture all possible parameter values that could
produce a good fit (defined as a predicted HIV prevalence within
the uncertainty interval provided by UNAIDS for the period 1995
to 2010 [1]), and randomly drew values from these distributions to
serve as model input. We ran the model with these parameter
values, and accepted parameter value combinations only when
they produced a good fit. For all parameter value combinations for
which this was the case, we recalculated all the outcomes of the
study.
For model D (the most comprehensive model in our analysis) we
repeated this procedure until we arrived at 120 alternative
parameter values that were accepted based on the above
mentioned criterion, and calculated all main outcomes of this
study with these alternative parameter settings. We developed
ranges reflecting parameter uncertainty by discarding the three
highest and lowest values for each outcome. For all other models
and sub-models, we repeated the procedure until we arrived at 40
alternative parameter values that were accepted, and discarded
only the single highest and lowest outcome values in order to
crudely arrive at the interval. We incorporated the intervals
resulting from this parameter uncertainty analysis as bars and
ranges in graphs and tables. A visual representation of all
parameter combinations that were used to calculate uncertainty
ranges, including the combinations that produced the highest and
lowest values that were later discarded, is given in Figure S4.
Scenarios and Outcomes
For all nine models we predicted the impact of a hypothetical
UTT intervention with annual screening of individuals aged 15+ y
and immediate ART for those who are infected with HIV, as
modeled by Granich et al., i.e., the intervention is scaled up
linearly to 90% coverage in seven years’ time (2012–2019), and
there is a dropout rate of 8.5% in the first year of treatment and
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1.5% in subsequent years [9]. We assume no further scale-up of
other prevention interventions (e.g., condom use, circumcision)
after 2012 in all models. Following Granich et al. we defined the
‘‘elimination phase’’ of HIV to start when HIV incidence drops
below 1 new infection per 1,000 person-years [9].
Furthermore, we calculated the cumulative number of life-years
saved and cumulative net costs of UTT compared to continued
scale-up of ART at CD4 count#350 cells/ml in model D, the only
model that incorporates enough detail to be able to adequately
represent the current scale-up of ART at CD4 count #350 cells/
ml in South Africa as the baseline of no UTT. We analyzed costs
from the health care sector perspective, and assumed ART costs
similar to those in Hontelez et al. [25]—where annual ART costs
were stratified by CD4 cell count at initiation and thereafter
dependent on the number of years on treatment (Table 2)—which
were derived from ART programs in Cape Town, South Africa
[55,56]. Costs include costs for ART provision, treatment of
opportunistic infections, outpatient visits, and inpatient days. Costs
were stratified by CD4 cell count at initiation since those initiating
treatment at late stages (low CD4 cell count) are more likely to
have opportunistic infections and other complications, thus
requiring more additional care. This difference disappears after
subsequent years of successful treatment. We assumed annual
ART costs for those initiating ART at CD4 cell counts of .350
cells/ml to be similar to the costs for those who initiated at 200–350
cells/ml and were on treatment for more than 2 y. For the UTT
scenario, in which treatment initiation is not guided by CD4 cell
count, we lowered all cost input values in the first year of treatment
by US$104 to subtract the cost of a CD4 cell count test [25]. We
discounted future costs and life-years saved by 3% annually [57].
Finally, we performed a sensitivity analysis on all the results
from model D by varying parameters of HIV natural history,
heterogeneity in HIV transmission, the state of the HIV epidemic
in South Africa, more and less optimistic UTT intervention
outcomes, and the assumptions on overall cost and scale effects.
Details on the sensitivity analysis can be found in Text S1.
Results
Figure 2 (left panels) shows the fit of all models to the HIV
prevalence in South Africa as reported by UNAIDS [1], together
with the projected impact of annual screening of individuals aged
15+ y and immediate ART for all HIV-infected patients at 90%
coverage. All models replicate the HIV prevalence in South Africa
in the period 1990–2010. However, as a result of the difference in
underlying processes in the structurally different models, the
corresponding HIV incidence levels are substantially different
(Figure 2, right panels). For example, the predicted incidence in
2011 for model A was 2.0/100 person-years, while for model D
this was only 1.0/100 person-years (right panels of Figure 2). Also,
projections regarding the future course of the HIV epidemic in the
absence of UTT differ substantially. Future incidence and preva-
lence in the absence of treatment reach a steady state in models A
and B, as indicated by the dashed lines. In model C, the incidence
and prevalence of HIV already decline in the no-intervention
scenario because of the increase in condom use in the early 2000s.
Such a decline is even more profound in model D, where current
ART scale-up in South Africa is included.
All models are consistent in predicting that HIV will eventually
be eliminated by UTT. However, the timing of elimination
significantly differs between the models (Figure 2; Table 3). In
model A, the HIV epidemic is driven into an elimination phase
after 7 y (range: 6; 9), while in models B, C, and D the elimination
phase is reached only after 39 (range: 30; 49), 21 (range: 19; 30),
and 17 (range: 15; 23) y, respectively. For model D, the HIV
incidence is even projected to reach the elimination phase in 2041
(range: 2037; 2047) without the full UTT intervention, because of
the impact of the current scale-up of ART at CD4 cell counts of
#350 cells/ml.
The sub-models B2, C1, and C3 do not predict elimination of
HIV by 2050 (Table 3; Figure S5). The combination of a high
background mortality and heterogeneity in HIV transmission
(model B2) results in a disproportionate contribution of acute
infection to the overall epidemic (as many HIV-infected patients
die because of other causes), thereby limiting the potential impact
of UTT. Heterogeneity in sexual behavior also prolongs the
predicted time to elimination (sub-model C1), as it accounts for
high-risk individuals who continue to spread HIV even in the
presence of ART. Finally, it is obvious that more up-to-date
assumptions on ART effectiveness result in a lower predicted
impact of UTT (sub-model C3), as the reduction in infectiousness
is lower (90% versus 99.4%) and survival is higher (twice as high
compared to Granich et al. [9]). On the other hand, explicitly
modeling background prevention interventions and STI co-factors
(sub-model C2) instead of using a simple prevalence density
function shortens the time until elimination, as the interventions
scaled up before 2012 affect the dynamics of the epidemic in the
long run, reducing incidence even without UTT or further scale-
up of other interventions (dashed line for model C in Figure 2).
There are substantial differences in the impact of UTT
compared to the no-UTT baseline in the different models, which
has important consequences for the effectiveness of the interven-
tion. By 2050, a cumulative total of 1,800 new infections per
100,000 person-years (range: 1,600; 2,500) would be averted in
model A, while this value is only 100 (range: 83; 150) in model D
(Figure 3A). Consequently, the predicted efficiency of ART in
Table 2. Cost input values used in this study.
CD4+ Count (in Cells/Microliter)
at ART Initiation Per Patient Annual ART Costs (US Dollars)
First Year Second and Third Year Subsequent Years
0–100 3,664 1,435 1,095
101–200 3,060 1,284 1,095
201–350 2,304 1,095 1,095
.350 1,095 1,095 1,095
Costs are stratified by CD4+ count at ART initiation, and include costs of diagnostic testing, ART provision, treatment of opportunistic infections, outpatient visits, and
inpatient days.
doi:10.1371/journal.pmed.1001534.t002
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Figure 2. Predicted impact of universal testing and immediate ART for all HIV-infected patients (UTT) on HIV prevalence and
incidence in adults (aged 15+ y) for four main models of the South African HIV epidemic over the period 1990–2050. Left panels: HIV
prevalence; right panels: HIV incidence. All models are structurally different. Solid lines represent the impact of the UTT intervention; the dashed lines
represent the no-UTT counterfactual. Colored lines are the average result of 1,000 simulations, and the gray areas represent the probability intervals
illustrating 95% of the stochastic variation around the baseline estimate. UTT is implemented as annual screening of the adult population (aged 15+
y), and immediate ART for all HIV-infected patients. The intervention is scaled up linearly, starting in 2012 and reaching 90% coverage in 2019 (similar
to Granich et al. [9]). The vertical dotted lines give the timing of the start of the intervention. The horizontal dotted lines in the right panels indicate
the elimination phase, defined as incidence below 1/1,000 person-years. Structures and components of the different models are explained in Figure 1.
doi:10.1371/journal.pmed.1001534.g002
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saving lives also differs substantially between models (Figure 3B).
Model A predicts about 5.7 cumulative life-years saved per
treatment year by 2050 (range: 4.7; 7.2), while in model D this
value is only 1.7 (range: 1.2; 2.6), almost four times lower.
Model D shows that cumulative net costs peak at US$3.8 billion
(range: 3.1 billion; 4.7 billion) at around 2020, and decline
thereafter as the impact of UTT on HIV incidence is translated
into a lower number of patients on treatment (Figure 4A).
Cumulative net costs reach about US$1.8 billion in 2050 (range:
0.25 billion; 3.5 billion). The effects of UTT will become apparent
only around the year 2020, when the prevented infections translate
into life-years saved (Figure 4B), and life-years saved increase
linearly to 10.4 million by 2050 (range: 5.6 million; 16.1 million).
The resulting incremental cost-effectiveness ratio is US$170/life-
year saved (range: 19; 406) (Table 4). All results are robust to
alternative assumptions and parameterizations (see sensitivity
analysis in Text S1 and Tables S6, S7, S8).
Discussion
Our study confirms previous reports that an intervention of
universal voluntary counseling and testing for individuals aged 15+
y and immediate ART for all HIV-infected individuals (UTT) at
90% coverage will eventually result in the elimination of HIV,
even in a highly endemic setting such as South Africa and with
realistic assumptions about the efficacy of ART in reducing HIV
transmission and enhancing survival. However, the predicted
timing of the elimination of HIV (defined as an incidence of below
one new infection per 1,000 person-years) differs substantially for
the different models in our study, and HIV elimination is likely to
take three times longer than the mere 7 y predicted by Granich
et al. [9]. In addition, the relative impact of the UTT intervention
compared to the baseline differs substantially. Whereas 1,800
infections are averted per 100,000 person-years (range: 1,600;
2,500) in the simplest model, this value is only 100 (range: 83; 150)
in the most comprehensive model. In fact, the latter model shows
that the current scale-up of ART for patients with CD4 cell counts
of #350 cells/ml already leads to elimination of HIV without the
additional UTT intervention. However, the considerable number
of life-years saved makes UTT at 90% coverage still a highly cost-
effective intervention, with an incremental cost-effectiveness ratio
of US$170/life-year saved (range: 19; 406).
Our sub-model analysis shows that choices in model structure
and assumptions have an important impact on the predicted
impact of UTT. It makes sense that more up-to-date assumptions
on the overall efficacy of ART in reducing infectiousness (90%
versus 99.4%) lead to delayed HIV elimination. Also, incorporat-
ing high infectiousness during the acute stage results in a less
profound impact of UTT, since relatively many transmission
events will then occur during this short period of high infec-
tiousness, which is difficult to target in UTT interventions [17,58].
Adding heterogeneity in sexual behavior and sexual networks to
the model also increases the time until elimination—this is because
the relative force of infection of HIV is high in certain high-risk
groups (e.g., FSWs) and therefore the impact of UTT is less
profound in these subgroups. Finally, explicitly modeling male
circumcision, condom use, and STI co-factors, and using increases
in condom use to quantify the HIV epidemic in South Africa [2,3],
decreases the time until HIV elimination, since the counterfactual
of no UTT already shows a substantial decline in incidence,
despite the fact that these interventions are not further scaled up in
the model after 2012. A model that relies on implicit modeling of
these interventions to capture the steady state (e.g., through a
prevalence density function, as was used by Granich et al. [9]) will
therefore overestimate the impact of UTT. Finally, it appears vital
to incorporate the current ART rollout in the counterfactual
scenario. The availability of ART in South Africa and many other
African countries is now a fact of life, and the rollout that generally
started in 2003–2004 is already affecting the epidemics through
increased survival and decreased transmission [2].
Given that the stepwise inclusion of model components
appeared to change the predicted impact of a UTT intervention,
Table 3. Year of HIV elimination (incidence ,1/1,000 person-years) under universal testing and immediate ART for all HIV-infected
patients (UTT) and number of life-years saved through UTT compared to the baseline of no UTT.
Model Sub-Model Year of Eliminationa (Range)
Life-Years Saved per ART
Treatment Year in 2050 (Range)
Model A 2019 (2018; 2021) 5.7 (4.7; 7.2)
+ Age structure (B1) 2019 (2018; 2020) 3.8 (3.1; 4.3)
+ Heterogeneity in HIV transmission
by disease stageb (B2)
2053 (2048; .2060) 2.6 (2.1; 3.3)
Model B (B1 and B2 combined) 2053 (2042; .2060) 3.0 (2.6; 3.5)
+ Sexual network (C1) .2060 (2058; .2060) 2.6 (1.8; 2.9)
+ Background prevention
interventions (C2)
2042 (2037; 2050) 2.8 (2.1; 3.2)
+ Up-to-date ART assumptions (C3) .2060 (2054; .2060) 2.9 (2.5; 3.1)
Model C (C1, C2, and C3
combined)
2032 (2030; 2041) 1.8 (1.1; 2.0)
Model D (STDSIM) 2029 (2027; 2034) 1.7 (1.2; 2.6)
Model D baseline (ART at CD4
count #350 cells/ml)
2041 (2037; 2047) N/A
UTT is scaled up linearly, starting in 2012 and reaching 90% coverage in 2019. Ranges reflect the variation in outcome due to the uncertainty in the parameter values
that were quantified based on fitting the model to the data.
aIncidence below 1/1,000 person-years.
bWe assumed four different stages: acute, asymptomatic, symptomatic, and AIDS.
N/A, not applicable.
doi:10.1371/journal.pmed.1001534.t003
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the model that incorporates all these components (model D) gives
the most accurate prediction of the impact. In addition, although
all models were able to accurately replicate the UNAIDS-reported
HIV prevalence in South Africa, model D was the only model that
was also able to capture the observed decline in incidence over the
past decade [2,3]. In model D, incidence in the population aged
15–49 y declined from 1.9/100 person-years in 2002 to 1.3/100
person-years in 2008, which is nearly the same as the observed
reduction from 2.0/100 person-years in 2002–2005 to 1.3/100
person-years in 2005–2008, as reported by Rehle et al. [3].
Incidence rates in the other models remained constant over the
same period (models A to C). In addition, model D was able to
replicate data on demographic structure, age-specific HIV
prevalence, sexual behavior, STI prevalence, and ART coverage
in South Africa (Figure S7; Text S2). Finally, previous studies with
STDSIM have shown that the model is capable of reproducing
HIV prevalence (overall and age- and sex-specific), incidence, and
mortality data from a population-based HIV and demographic
surveillance site in KwaZulu-Natal, South Africa [25,36,37,59,60].
The simulated impact of ART in this highly endemic area of
South Africa [25] was very similar to what was recently observed
by Tanser et al. [5], providing reassurance that our model predic-
tions are accurate.
To our knowledge, this is the first study that shows that the
current rollout of ART for all HIV-infected patients with CD4 cell
counts of #350 cells/ml will eventually eliminate HIV. This raises
questions about the value for money of the additional investments
required to implement UTT. Although we show that the UTT
intervention proposed by Granich et al. [9] is highly cost-effective,
the required number of health workers and financial resources for
such a strategy far exceeds the current availability in South Africa
[61]. Also, the assumed rates of HIV testing, ART uptake,
retention in care, and treatment adherence are rather optimistic
[62,63]. Adherence and retention are likely to decrease when
treatment is initiated at higher CD4 cell counts [64], while the
number of patients lost to follow-up increases when treatment
programs are scaled up [65]. Both these issues are especially
important in UTT strategies, where patient numbers increase
substantially, and many patients initiate ART at high CD4 cell
counts. In addition, maintaining screening coverage levels at 90%
for 40+ y seems not very plausible. It is likely that test refusal will
be substantially higher than the 10% assumed in our analyses [66],
increase over time [67], and be more common among people with
HIV [67], resulting in a lower and declining screening coverage
over time. Still, our sensitivity analysis shows that UTT would
remain a cost-effective strategy, even with coverage rates of only
60%. A recent study on the cost-effectiveness of ART provision in
South Africa showed that cost savings will be achieved after just
5 y of UTT at 90% coverage [68], while our modeling indicates
that there will be no net savings from this UTT intervention in
South Africa. The underlying compartmental transmission model
Figure 3. Number of infections averted per 100,000 person-
years and cumulative number of life-years saved per ART
treatment year for universal testing and immediate ART for all
HIV-infected patients (UTT) in South Africa over the period
2010–2050. The intervention consists of annual screening of the adult
population (aged 15+ y), and immediate ART for all HIV-infected
patients. Intervention is scaled up linearly starting in 2012 and reaching
90% coverage in 2019. (A) Difference between cumulative numbers of
new infections per 100,000 person-years in the UTT intervention
scenario versus the baseline (for models A, B, and C, the baseline is no
ART; for model D, the baseline is ART at CD4 count #350 cells/ml). (B)
Cumulative number of life-years saved per person-year on ART
treatment in the UTT intervention compared to the baseline (for
models A, B, and C, the baseline is no ART; for model D, the baseline is
ART at CD4 count #350 cells/ml). Error bars reflect ranges due to the
uncertainty in the parameter values that were quantified based on
fitting the model to the data.
doi:10.1371/journal.pmed.1001534.g003
Figure 4. Cumulative net costs and cumulative number of life-
years saved of universal testing and immediate ART for all HIV-
infected patients (UTT) compared to the current rollout in
South Africa of ART at CD4 count #350 cells/ml, as predicted
with model D. (A) Cumulative net costs; (B) cumulative number of life-
years saved. Grey lines represent 100 individual model runs illustrating
stochastic variation; black lines are averages over 1,000 model runs.
Error bars reflect ranges due to uncertainty in the parameter values that
were quantified based on fitting the model to data. Costs and life-years
saved were discounted at an annual rate of 3%.
doi:10.1371/journal.pmed.1001534.g004
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in that study [68] is essentially the same as that previously used by
Granich et al. [9,68], and thus resembles our model A. We show
that these types of models, which ignore sexual networks and
background prevention interventions underlying the current South
African epidemic, predict a far more optimistic impact of UTT
compared to the baseline. Cost-effectiveness and economic impact
studies based on such models should therefore be interpreted with
caution. More research with comprehensive models of the impact
of more modest UTT interventions is necessary in order to
determine whether universal treatment for HIV really is a cost-
effective intervention.
Our study has a number of limitations. We defined elimination
as incidence below 1/1,000 person-years. However, real elimina-
tion is achieved when both incidence and prevalence reach 0%.
Microsimulation allows for such an analysis, and we found that in
a model population of about 35,000 people, by 2080, 99% of all
model runs predict that HIV prevalence reaches 0% in model A
(Figure S5). In model D this point is reached only in year 2116 for
the UTT scenario, and in year 2164 for continued scale-up of
ART at CD4 count #350 cells/ml (Figure S5). In addition, we did
not model the development and transmission of drug-resistant
strains. Both acquired resistance (development of resistance within
an individual on treatment) and transmitted resistance (spread of
drug-resistant strains) will have an impact on the effectiveness of
treatment programs, and will consequently result in a less
profound effect of the current ART scale-up or UTT in South
Africa. It is currently unclear, however, to what extent the fears of
rapidly spreading drug resistance expressed at the start of the ART
scale-up were justified [69]. The prevalence of drug resistance
remains low in South Africa after nearly 10 y of scaling up ART
[70,71]. In addition, adherence to treatment is as high as in many
high-income countries [72], and survival of patients on treatment
in sub-Saharan Africa approaches general life expectancy [73],
suggesting that resistance may not become a major problem in
South Africa in the near future.
Elimination of HIV in South Africa will have huge implications
for public health and socioeconomic development in the country.
The current ART rollout is already resulting in a substantial
increase in the life expectancy of the general population [74] and
in the employment rates of HIV-infected people [75]. Finally,
elimination of HIV will also substantially reduce the tuberculosis
burden in South Africa, given the close link between the two
epidemics [76].
In conclusion, our results from a series of structurally different
models support the main message from previous studies that HIV
in South Africa can be eliminated through a strategy of annual
screening of individuals aged 15+ y and immediate ART for all
HIV-infected patients at 90% coverage, but elimination will occur
substantially later than previously predicted. Importantly, the most
comprehensive model suggests that HIV incidence in South Africa
can reach the elimination phase even if the current treatment
scale-up of ART at CD4 count #350 cells/ml continues without
the addition of a UTT intervention. Results from upcoming
community randomized trials of treatment as prevention will need
to be evaluated with models that allow for sufficient detail in
assumptions in order to adequately project the population-level
impact and overall cost-effectiveness of the UTT intervention.
Supporting Information
Figure S1 Demographic input parameters. (A) Total
fertility rates (lifetime number of births/woman) over time. Data
obtained from the UN World Fertility Data 2008 database [39].
(B) Background mortality (mortality in the absence of AIDS)
obtained from WHO [40]. All cause mortality rates were corrected
using WHO burden of disease estimates of HIV mortality rates in
South Africa [41] in order to obtain estimates of non-AIDS-related
mortality rates in South Africa.
(TIF)
Figure S2 Distribution of number of partners (steady
and casual) in the last 12 mo by age and sex. Results follow
from parameter settings described in Tables S2–S4.
(TIF)
Figure S3 Distribution of number of partners in the last
12 mo (steady and casual) by age and sex in 2003 (after
change in overall partner change rates). Results follow from
parameter settings described in Tables S2–S4 and above described
adjustment in overall partner change rates.
(TIF)
Figure S4 Parameter combinations used to create
uncertainty ranges around the baseline estimates for
models A to D. Because of underlying structural differences,
different parameters were used to fit the models to UNAIDS-
reported HIV prevalence data. Our approach to developing
parameter combinations and uncertainty ranges is described in the
Methods (‘‘Model Fitting and Parameter Uncertainty’’). Light-blue
dots and lines indicate parameter combinations that produced the
highest and lowest estimates of impact; these estimates were
omitted to create 95% uncertainty ranges. For models A and B, we
used the HIV introduction year and HIV transmission probabil-
ities (left panels) and the x parameter in the prevalence density
function p(t1) = p(t0)6e
2xP, where p = HIV transmission probability
and P = HIV prevalence (right panels), to fit the model. For models
C and D, we used the relative partner change rates and
Table 4. Effects, cost, and cost-effectiveness of universal test and treat versus continued scale-up of ART at CD4 count #350 cells/
ml in South Africa over the period 2012–2050 (Model D).
Strategy
Cumulative Life-Years
(Millions) (Range)
D Life-Years (Millions)
(Range)
Cumulative Costs
(Millions of US Dollars)
(Range)
D Cost (Millions of
US Dollars) (Range)
Incremental Cost-
Effectiveness Ratio (US
Dollars/Life-Year Saved)
(Range)
ART at CD4 count
#350 cells/ml
1,290 (1,200; 1,360) — 76,900 (67,700; 90,100) — —
UTT 1,300 (1,210; 1,380) 10.4 (5.6; 16.1) 78,600 (69,100; 93,200) 1,780 (250; 3,470) 170 (19; 406)
Costs and effects are discounted at an annual rate of 3%. Life-years concern the total life-years lived in South Africa of the entire population. Of these total life-years, 7%
are life-years lived with HIV. Ranges reflect the variation in outcome due to the uncertainty in the parameter values that were quantified based on fitting the model to
the data.
doi:10.1371/journal.pmed.1001534.t004
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introduction year of HIV (left panels) and the increase in condom
use rates (right panels).
(TIF)
Figure S5 Cumulative distribution of year of achieving
0% incidence and prevalence of individual model runs
for all main models. Results are based on 400 model runs.
(TIF)
Figure S6 Predicted impact of universal testing and
immediate ART for all HIV-infected patients (UTT) on
HIV prevalence (left panels) and incidence (right panels)
in adults (aged 15+ y) for five sub-models of the South
African HIV epidemic over the period 1990–2050. Colored
lines are the average result of 1,000 simulations, and the grey areas
represent the probability intervals based on the stochastic variation
between individual model runs. UTT is implemented as annual
screening of the adult population, and immediate ART for all
HIV-infected patients. The intervention is scaled up linearly,
starting in 2012 and reaching 90% coverage in 2019 (similar to
Granich et al. [9]). The vertical dotted lines give the timing of the
start of the intervention. The horizontal dotted lines in the right
panels indicate the elimination phase, defined as incidence below
1/1,000 person-years. The same figures for the four main models
are given in Figure 2.
(TIF)
Figure S7 Model fit compared to data (model D). (A)
Projected demographic structure of South Africa in 2011: model
compared to UN data [77]. (B) Age-specific HIV prevalence
(model compared to data [78]) in 2008. (C) Age-specific
distribution in number of partners in the last 12 mo for men.
(D) Age-specific distribution in number of partners in the last
12 mo for women. (E) Trend in prevalence of STIs in men: model
compared to estimates from Johnson et al. [79]. (F) Trend in
prevalence of STIs in women: model compared to estimates from
Johnson et al. [79]. (G) Projected ART coverage in South Africa:
model versus WHO data [53]. (H) Projected total number of
people on ART in South Africa: model versus WHO data [53]. (I)
Cumulative distribution of CD4 cell counts at first HIV test: model
compared to data from KwaZulu-Natal, South Africa [25,80]. (J)
Average remaining life expectancy at treatment initiation by CD4
cell count at treatment initiation: model compared to data [51].
(TIF)
Figure S8 Predicted HIV prevalence for all sensitivity
analyses (except for alternative economic and UTT
performance assumptions) compared to UNAIDS-re-
ported HIV prevalence in South Africa [1]. Parameter
assumptions are given in Tables S6 and S7.
(TIF)
Table S1 Annual probability of a woman having a child,
by age group. Distribution over age groups according to UN
data [39].
(DOCX)
Table S2 Sexual behavior parameters. Justification for the
age distribution in promiscuity, frequency of contact, and duration
of partnerships can be found in Orroth et al. [35] and Korenromp
et al. [30]. All age-specific promiscuity values (i.e., overall partner
change rates) were adjusted with the same factor in order to
represent the HIV epidemic observed in South Africa.
(DOCX)
Table S3 Age preference matrix for men and women.
Same as in previous STDSIM studies [25,30,35]. Justification for
the values can be found in Korenromp et al. [30].
(DOCX)
Table S4 Parameter settings for commercial sex. Same
as in previous STDSIM studies [25,35]. Justification can be found
in Orroth et al. [35].
(DOCX)
Table S5 Parameter settings for natural history of
simulated STIs. Same as previously used in other studies
[25,35]. ‘‘Lack of circumcision’’ effect represents factor increase in
susceptibility to the STI for men who are not circumcised, i.e.,
uncircumcised men are twice as likely to get infected during an
unprotected sex act with an infected partner. Justification can be
found in Orroth et al. [35].
(DOCX)
Table S6 Alternative assumptions on HIV natural
history and transmission probabilities for sensitivity
analyses. Infectiousness in the asymptomatic stage, condom use,
and the year of HIV introduction are used to fit predicted HIV
prevalence to the UNAIDS data [1].
(DOCX)
Table S7 Input parameters for sensitivity analysis on
the course of the epidemic.
(DOCX)
Table S8 Results of the sensitivity analysis. The year of
elimination is defined as the first year HIV incidence drops below
1/1,000 person-years. UTT is universal testing of individuals aged
15+ y and immediate treatment for all HIV-infected patients,
starting in 2012 and scaled up to 90% coverage in 2019.
(DOCX)
Text S1 Sensitivity analysis.
(DOCX)
Text S2 Model fit to data.
(DOCX)
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Editors’ Summary
Background. About 34 million people (mostly in low- and
middle-income countries) are currently infected with HIV, the
virus that causes AIDS, and every year another 2.5 million
people become infected. HIV, which is usually transmitted
through unprotected sex with an infected partner, gradually
destroys CD4 lymphocytes and other immune system cells,
leaving infected individuals susceptible to other infections.
Early in the AIDS epidemic, people infected with HIV often
died within ten years of infection. Then, in 1996, antiretro-
viral therapy (ART) became available, and, for people living in
affluent countries, HIV/AIDS became a chronic condition.
However, ART was expensive, so HIV/AIDS remained a fatal
condition for people living in resource-limited countries. In
2006, the international community set a target of achieving
universal ART coverage by 2010, and ART programs were
initiated in many resource-limited countries. Although
universal ART coverage has still not been achieved in South
Africa, where nearly 6 million people are HIV-positive, 80% of
people in need of ART were receiving a World Health
Organization–recommended ART regimen by October 2012.
Why Was This Study Done? ART is usually started when a
person’s CD4 count falls below 350 cells/ml blood, but it is
thought that treatment of all HIV-positive individuals,
regardless of their CD4 count, could reduce HIV transmission
by reducing the infectiousness of HIV-positive individuals
(‘‘treatment as prevention’’). Might it be possible, therefore,
to eliminate HIV by screening everyone annually for infection
and treating all HIV-positive individuals immediately? In
2009, a mathematical modeling study suggested that seven
years of universal test and treat (UTT) could eliminate HIV in
South Africa. The deterministic (nonrandom) model used in
that study has been widely criticized, however, and some
subsequent modeling studies have reached different con-
clusions, probably because of differences in the models’
structures and in the assumptions built into them. A better
understanding of the reasons for the discrepancies between
models would help policy-makers decide whether to
introduce UTT, so, here, the researchers developed several
increasingly complex and realistic models of the South
African HIV epidemic and used these models to predict the
long-term impact of UTT in South Africa.
What Did the Researchers Do and Find? The researchers
developed nine structurally different mathematical models
of the South African HIV epidemic based on the STDSIM
framework, a stochastic microsimulation model that simu-
lates the life course of individuals in a dynamic network of
sexual contacts and in which events such as HIV infection are
random processes. The simplest model, which resembled the
original deterministic model, was extended by sequentially
adding in factors such as different HIV transmission rates at
different stages of HIV infection and up-to-date assumptions
regarding the ability of ART to reduce HIV infectiousness. All
the models replicated the prevalence of HIV in South Africa
(the proportion of the population that was HIV-positive)
between 1990 and 2010, and all predicted that UTT (defined
as annual screening of individuals age 15+ years and
immediate ART for all HIV-infected adults starting in 2012
and scaled up to 90% coverage by 2019) would result in HIV
elimination (less than one new infection per 1,000 person-
years). However, whereas the simplest model predicted that
UTT would eliminate HIV after seven years, the more
complex, realistic models predicted elimination at much
later time points. Importantly, the most comprehensive
model predicted that, although elimination would be
reached after about 17 years of UTT, the current strategy
of ART initiation for HIV-positive individuals at a CD4 cell
count at or below 350 cells/ml would also lead to HIV
elimination, albeit ten years later than UTT.
What Do These Findings Mean? These findings confirm
previous predictions that UTT could eliminate HIV in South
Africa, but the development of more realistic models than
those used in the past suggests that HIV elimination would
occur substantially later than originally predicted. Impor-
tantly, the most comprehensive model suggests that HIV
could be eliminated in South Africa using the current
strategy for ART treatment alone. As with all modeling
studies, the accuracy of these findings depends on the
assumptions built into the models and on the structure of
the models. Thus, although these findings support the use of
UTT as an intervention to eliminate HIV, more research with
comprehensive models that incorporate factors such as data
from ongoing trials of treatment as prevention is needed to
determine the population-level impact and overall cost-
effectiveness of UTT.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001534.
N This study is further discussed in a PLOS Medicine
Perspective by Ford and Hirnschall
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV and AIDS in South Africa, on HIV treatment as
prevention and the possibility of HIV elimination (in
English and Spanish)
N The 2012 UNAIDS World AIDS Day Report provides up-to-
date information about the AIDS epidemic and efforts to
halt it
N The World Health Organization provides information about
universal access to AIDS treatment (in several languages);
its 2010 ART guidelines can be downloaded
N The PLOS Medicine Collection ‘‘Investigating the Impact of
Treatment on New HIV Infections’’ provides more infor-
mation about HIV treatment as prevention
N Personal stories about living with HIV/AIDS are available
through Avert, through NAM/aidsmap, and through the
charity website Healthtalkonline
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